Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting

On May 12, 2025 Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies reported that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and two poster sessions at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th annual meeting in New Orleans, LA from May 13th to 17th (Press release, Grit Bio, MAY 12, 2025, View Source [SID1234652897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Grit Bio will provide the updates of three preclinical programs, including APC-targeted neoantigen cancer vaccine, non-viral-nanoparticle-directed in vivo CAR-T, and LNP-mediated gene editing in tumor infiltrating lymphocyte (TIL). The details of three presentations are:

Title: APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses
Presentation Type: Oral
Time: 5:15-5:30 pm local time, Thursday, May 15th
Speaker: Pin Wang, Ph.D., CSO of Grit Biotechnology
Title: In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery
Presentation Type: Poster
Time: 5:30-7:00 pm local time, Wednesday, May 14th
Poster #: 1282
Title: Enhancing Production and Functional Potential of Tumor-Infiltrating Lymphocytes via Lipid Nanoparticle-Mediated CRISPR/Cas9 Gene Editing
Presentation Type: Poster
Time: 5:30-7:00 pm local time, Thursday, May 15th
Poster #: 1776
"Through a strategic collaboration with Vitalgen, we are pioneering next-generation immunotherapies and precision delivery technologies. This synergy accelerates the development of advanced therapies with transformative improvements in safety and efficacy. We are now expanding those innovations toward global clinical implementation." said Dr. Yarong Liu, founder and Chief Executive Officer of Grit Biotechnology.